News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DaVita Inc. (DVA) Acquires Majority Stake in Lehbi Care, Saudi Arabia


4/5/2012 9:33:19 AM

DENVER & RIYADH, Saudi Arabia--(BUSINESS WIRE)--DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), today announced it has acquired a controlling interest in Lehbi Care, a leading Riyadh-based kidney care company. DaVita® will actively manage the three Lehbi clinics in operation in Riyadh and is planning to expand home modality options and build a vascular access center.

“Saudi Arabia is an important market for DaVita in the Middle East,” said DaVita Chairman and CEO Kent Thiry. “We will continue to look for areas of solid, long-term growth that are a fit and close a gap in needed services.”

Lehbi Care currently treats 400 patients at three hemodialysis clinics throughout Riyadh. Patients will have greater access to treatment options and more effective care with a vascular access center and home hemodialysis and peritoneal dialysis.

“It has been exciting to develop a strong relationship with Dr. Allehbi and the nurses,” said Dennis Kogod, DaVita chief operating officer. “The collaboration between DaVita and Lehbi Care will be one where both sides gain and patients benefit.”

As a leading provider of kidney care services in the United States, DaVita has achieved clinical outcomes that have improved year-over-year for more than a decade and will share that expertise through its active management of the company.

“To have DaVita as a partner and utilize their expertise is a gift to the Lehbi staff and patients,” said Dr. Ali Mohammed Allehbi, founder of Lehbi Care.

DaVita® is a registered trademark of DaVita Inc. All other trademarks are the property of their respective owners.

About DaVita

DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of December 31, 2011, DaVita operated or provided administrative services at 1,809 dialysis facilities in the United States, serving approximately 142,000 patients. The company also operated 11 outpatient dialysis centers located in three countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit www.davita.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the federal securities laws, including statements related to prospective near-term and long-term growth, development and strategy for certain of our international operations, expected patient benefits and projected clinical outcomes. Factors which could impact future results include the risks and uncertainties associated with expansion of our operations and services to markets outside the United States, local laws and regulations, general economic and other market conditions, competition, and the risk factors set forth in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2011. The forward-looking statements should be considered in light of these risks and uncertainties. We base our forward-looking statements on information currently available to us at the time of this release, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of changes in underlying factors, new information, future events or otherwise.

Contacts

DaVita Inc.

Media:

Skip Thurman, 303-405-2296

Skip.Thurman@DaVita.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES